A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer

Trial Profile

A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2016 Results of final analysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2016 According to an Eisai Co., media release, results from this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
    • 15 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top